CAU
CTKB icon

Caxton Associates (UK)’s Cytek Biosciences CTKB Stock Holding History

Caxton Associates (UK)’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-45,376
Closed -$229K – 827
2025
Q4 		$229K Sell
45,376
-48,032
-51% -$223K ﹤0.01% 684
2025
Q3 		$324K Sell
93,408
-10,057
-10% -$37.8K 0.01% 539
2025
Q2 		$352K Buy
103,465
+1,571
+2% +$5.24K 0.01% 509
2025
Q1 		$409K Buy
+101,894
New +$528K 0.01% 543

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Caxton Associates (UK)'s CTKB Position: Q1 2026 in Review

Caxton Associates (UK) sold out of Cytek Biosciences (CTKB) in Q1 2026, closing a stake of 45,376 shares — an estimated $229K sold.

Caxton Associates (UK) first reported a position in CTKB in Q1 2025 and held it in 4 quarters. The position peaked at $409K in Q1 2025. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Caxton Associates (UK) reported no remaining Cytek Biosciences position as of Q1 2026 after selling out during the quarter.
  • Caxton Associates (UK) sold 45,376 Cytek Biosciences shares in Q1 2026, an estimated $229K.
  • Caxton Associates (UK) first reported a position in Cytek Biosciences in Q1 2025 and held it in 4 quarters.
  • Caxton Associates (UK)'s Cytek Biosciences position peaked at $409K in Q1 2025.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Caxton Associates (UK)'s 13F filing for Q1 2026, filed 14 May 2026.